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A B S T R A C T
A 5-year-old neutered female toy Poodle chronically treated with systemic and topical azoles to control recurrent
Malassezia dermatitis/otitis was presented because of the loss of treatment efficacy. Minimum Inhibitory
Concentrations (MICs) obtained in vitro for various azoles (especially itraconazole and ketoconazole) against
Malassezia strains isolated from the dog were increased by several-fold compared with MICs obtained for control
isolates. These results reinforced the assumption based on clinical observation, i.e. the development of azole
resistance
1. Introduction
Malassezia pachydermatis is a lipophilic yeast that colonizes the
stratum corneum and mucosal sites of dogs. Favorable growth condi-
tions in the local environment allow excessive multiplication of this
organism, which may then function as an opportunistic secondary pa-
thogen [1]. Dogs may present with Malassezia otitis, dermatitis (either
localized or generalized) or both. Clinical signs are variable and include
erythema, alopecia, mild–to-severe pruritus, greasy exudation and
scaling. Secondary lesions include excoriations, lichenification, hy-
perpigmentation and exudation. In generalized cases, a rancid odor is
commonly reported [1].
The yeast overgrowth is generally secondary to an ongoing disorder,
predominantly hypersensitivity diseases (especially atopy), keratiniza-
tion defects, recurrent bacterial pyoderma and endocrine diseases
(especially hypothyroidism) [1]. Both in the case of dermatitis and
otitis, a hypersensitivity response to the yeast itself is likely to occur in
many allergic dogs [1]. Breed predisposition appears to be an important
risk factor and cases without apparent underlying causes have also been
reported [2].
Therapeutic options for treating Malassezia otitis/dermatitis include
systemic and/or topical antifungal agents belonging to various che-
mical classes. Azole compounds, which inhibit the fungal biosynthesis
of ergosterol by interacting with sterol-14α-demethylase [3], are widely
employed [1]. Various antiseptics, such as chlorhexidine, are also ef-
fective treatments [1].
The possibility of developing azole resistance by M. pachydermatis
has been frequently claimed in the literature on the basis of in vitro
tests (e.g.in the studies by Nijima et al. [4] and Jesus et al.[5]), but only
one case of in vivo resistance (i.e. treatment failure) has been reported,
to date, in the dog [6]. Here we describe another case of M. pachy-
dermatis that displayed in vivo resistance to azole compounds.
2. Case
A 2.5-year-old neutered female toy Poodle was evaluated (day 0) for
severe, recurrent, generalized Malassezia dermatitis and otitis. Possible
predisposing causes (allergic dermatitis, hypothyroidism, leishmaniasis,
ecto-parasite infestation etc.) were investigated and ruled out. Due to
the “idiopathic” nature of the yeast overgrowth, the following protocol
was adopted: itraconazole oral solution (Itrafungol® Eli Lilly Italia Spa,
Sesto Fiorentino, Italy) 5mg/kg twice a week on 2 consecutive days;
2% chlorhexidine and 2% miconazole shampoo (Malaseb®, Dechra
Veterinary Products A/S, Denmark) once a week; ear drops containing
miconazole, prednisone and polymyxin B (Surolan®, Elanco Animal
Health; Basingstoke, UK), applied twice a day for 2 weeks whenever
needed. This protocol allowed an excellent control of clinical signs, as
well as a reduction in the number of yeast cells detected on skin and ear
cytological samples. The treatment protocol had to be maintained on a
long-term basis, since dermatological problems recurred when with-
drawal was attempted.
About two years and a half later (day+ 900), although the therapy
had not been changed, severe scaling dermatitis, pruritus and offensive
odor developed, associated with an increase in the number of yeast cells
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in the skin and ear cytological samples. Treatment frequency was in-
creased, as follows: itraconazole oral solution 5mg/kg once daily; 2%
chlorhexidine and 2% miconazole shampoo every 2 days. However,
there was neither improvement in dermatological signs, nor a reduction
in the number of yeast cells in skin and ear cytological samples.
The dog was presented for a new evaluation (day+930). The
dermatological picture consisted of numerous small white and yellow
scales distributed over the entire surface of the body, including the
limbs and the head, which were loosely attached to the hairs or stuck to
the skin surface, partial alopecia together with pruritus and marked
offensive odor (Fig. 1). Bilateral ceruminous otitis was also present
(Fig. 2). Numerous Malassezia yeasts (> 30× high-power field) were
detected on multiple skin and ear cytological samples (Fig. 3).
Parasitic diseases and concurrent bacterial or dermatophyte infec-
tions were ruled out based on the administration of selamectin spot on
(Stronghold® Zoetis 1348 Louvain-la-Neuve, Belgium) skin scrapings,
direct hair examination, cytology and fungal cultures.
The worsening of an unidentified predisposing condition, a con-
comitant immunosuppressive disease, or the presence of azole re-
sistance were considered as possible causes for the loss of treatment
efficacy. Concomitant systemic or dermatological problems were not
detected despite extensive clinical and laboratory investigations, in-
cluding complete blood cell count, serum biochemistry panel, ur-
inalysis, haemostatic profile, thyroid hormones and TSH measurement.
In order to investigate possible azole resistance, acetate tape and swab
samples were collected from different body areas and both ear canals
and sent to a mycological research laboratory (day+ 940).
All samples, cultured on Sabouraud dextrose agar (SDA) with
chloramphenicol and gentamycin at 30 °C, yielded a profuse growth of
yeast colonies with microscopic appearance typical ofM. pachydermatis.
The isolates employed for the in vitro tests (see below) were deposited
in the collection of the Westerdijk Institute (formerly the Fungal
Biodiversity Center – CBS) of Utrecht, where identification was con-
firmed at the molecular level.
2.1. Antifungal susceptibility testing (day+ 950)
Three isolates were tested for the susceptibility to the following
antifungal agents:
- miconazole (MCZ), clotrimazole (CTZ) and terbinafine (TER) using a
microplate broth-dilution (MiB) method modified from the re-
ference method for in vitro testing of yeasts by the Clinical and
Laboratory Standard Institute (CLSI) [7] (method described in
document S1).
- fluconazole (FCZ) and posaconazole (PSZ) using a commercial kit
(E-test®, bioMérieux) (method described in document S1).
- itraconazole (ITZ) and ketoconazole (KTZ), using both methods.
Results were expressed as MICs (minimum inhibitory concentrations
of a drug able to inhibit fungal growth) [7]. For comparison, a reference
strain (strain CBS 1879, considered the M. pachydermatis “type strain”)
was included in the tests. For ITZ, KTZ, MCZ and CTZ, MICs were also
compared with MICs – available in the database of the laboratory -
previously obtained for 10 isolates of the yeast coming from dogs never
subjected to antifungal therapies.
MICs of different azoles – in particular of ITZ, KTZ and MCZ – were
increased by several-fold compared with MICs obtained for the control
isolates (Table 1; Fig. 4).
These results reinforced the assumption based on clinical observa-
tion, i.e. the development of azole resistance.
Topical and systemic azoles were replaced with TER (Lamisil®,
Novartis Pharma AG; Basel, Switzerland; 30mg/Kg per os once a day)
[8,9]. However, during the following month (day + 960–990), clinical
signs worsened. Oral TER was thus suspended and an exclusively to-
pical approach was attempted with 4% chlorhexidine digluconate
shampoo (Chlorexyderm® 4%, ICF, Cremona, Italy) performed every 2
days and an otic gel containing TER, dexamethasone and florphenicol
Fig. 1. Severe generalized scaling dermatitis due to M. pachydermatis in a 5-
year-old neutered female toy Poodle. A large amount of scales has been shed on
the surface of the consulting table.
Fig. 2. Scaling dermatitis with very mild erythema of the inner aspect of the
pinna in the same dog as in picture 1. Ceruminous otitis was also present.
Fig. 3. Numerous Malassezia yeasts visible on skin cytological sample (adhesive
tape preparation, 40×) from a toy Poodle dog with severe generalized scaling
dermatitis (Bar 10 µm).
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(Osurnia®, Elanco Animal Health; Basingstoke, UK, twice a day). After 1
month (day + 1020), skin and ear lesions had significantly improved,
but moderate pruritus and offensive odor were still present. Un-
fortunately, at that time cytology was not performed. Since then, dif-
ferent shampoos containing chlorhexidine, miconazole, zinc gluconate
and colloidal sulphur are being employed on a rotating basis, with a fair
control of the clinical signs. Moreover, during rechecks, a large number
of Malassezia yeasts are always detected at cytology.
Eleven months later (day+1350), other isolates were obtained in
culture and tested in vitro. MICs for these isolates were consistently
higher than those for the control isolates (Table 1).
3. Discussion
This case confirms what has been reported recently [6], namely that
azole resistance can be the cause of treatment failure in a dog with
Malassezia dermatitis/otitis. The previous report of resistance [6]
concerned a 15-year old Miniature Dachshund dog in Japan, where
resistance was suspected because of the lack of response despite 23 days
of once-daily oral therapy with ITZ (8mg/kg) and weekly shampooing
with 2% miconazole/2% chlorhexidine shampoo. The clinical history
regarding the dog was not provided, in particular nothing was said
about previous antifungal treatments [6]. On the contrary, our dog was
followed over an extended period, which allowed us to document that a
prolonged exposure (years of treatment) to azole agents was required to
develop resistance.
Antifungal susceptibility testing for M. pachydermatis must be in-
terpreted with caution, as reference methods are not available [10]. To
overcome this limit we used two methods (i.e. MiB and E-test) [11–13]
and we compared the MICs of the isolates from the index case with the
MICs obtained for some field isolates and a reference strain of the yeast.
Not unexpectedly, the absolute values were somewhat different be-
tween the two methods (Table 1), but the same trend was observed, i.e.
MICs of different azoles were increased for the six isolates compared
with the control ones. One isolate in particular (strain CBS 15216) was
highly resistant to MCZ and ITZ (where, in some cases, no MIC was
detected, Fig. 4). These findings suggest that the skin of a given dog
may be colonized by strains of M. pachydermatis with different anti-
fungal susceptibility profiles. This possibility has already been shown
for different bacterial species involved in canine otitis externa [14].
Interestingly, azole agents that had not been used in this dog (PSZ,
FCZ, KTZ) showed a reduced activity in vitro, suggesting a possible
cross-resistance of M. pachydermatis to different azoles. This phenom-
enon has been hypothesized in previous studies based on in vitro results
[5].
Oral TER was ineffective in controlling clinical signs, despite there
being a less marked difference between the MICs of the isolates and the
reference strain (Table 1). This could be due to the lower concentrations
of TER in canine stratum corneum or sebum compared to serum [15].
However, TER was active when employed topically, which can be ex-
plained by the concentration of active principle in the commercial
formulation (Osurnia®), which greatly exceeds the MIC, being in the
order of mg/ml.
The fact that chlorhexidine only allowed partial control of clinical
signs is surprising as an antiseptic should also maintain its activity
against an azole-resistant strain of M. pachydermatis. This possible in-
congruence could be explained by considering that the dog suffered
from an “idiopathic” form of Malassezia dermatitis and otitis, and in
such cases topical therapy alone is often insufficient [2].
Another important consideration is that the MICs for the isolates
sampled at a later date were consistently higher than those for the
control isolates (Table 1). This may indicate that resistance in M. pa-
chydermatis, once established, is stable.
Very little is known regarding possible mechanisms of resistance to
azoles in M. pachydermatis. Iatta et al. [16] reported that resistance may
depend on increased efflux by pumps, particularly those belonging to
the “major facilitator superfamily”. The underlying cause may also be
Table 1
MICs (µg/ml) for six isolates ofM. pachydermatis obtained from the toy Poddle dog, a reference strain and 10 isolates of the yeast coming from dogs never subjected to
antifungal therapies.
ITZ KTZ MCZ TER CTZ PSZ FCZ
Number Provenance MiB E-test MiB E-test MiB MiB MiB E-test E-test
CBS 15214a skin (abdomen) 0.5 0.75 2 0.75 16 1 32 1.5 > 256
CBS 15215a skin (dorsum) 1 0.75 2 1 16 1 16 1.5 128
CBS 15216a right ear 8 > 32 16 1.5 > 32 4 16 4 > 256
CBS 15208b right ear 1 0.75 4 1 16 1 32 2 128
CBS 15212b skin (neck) 1 0.5 4 0.75 16 2 32 1.5 > 256
CBS 15211b skin (left thigh) 1 0.75 4 0.5 16 2 32 1.5 > 256
CBS 1879 reference strain 0.03 0.125 0.25 0.125 2 0.5 4 0.25 12
/ dogs never subjected to antifungal therapiesc 0.016–0.06 0.023–0.094 0.03–0.125 0.19–0.125 1–4 / 1–16 / /
a,b = obtained from the toy Poddle dog, a) on day +940; b) at the occasion of a follow up visit (day+1350); c = for these isolates (n=10) the range of MICs
obtained is provided.
Number= the accession number assigned by the fungal collection of the Westerdijk Institute (formerly the Fungal Biodiversity Center – CBS) of Utrecht.
MiB=microplate broth-dilution method. ITZ= Itraconazole; MCZ=Miconazole; TER=Terbinafine; KTZ=Ketoconazole; CTZ=Clotrimazole;
PSZ=Posaconazole; FCZ=Fluconazole.
Fig. 4. Results of the E-test assay for two isolates of M. pachydermatis against
itraconazole. Left: reference strain CBS 1079 (MIC 0.125 µg/ml); right: isolate
CBS 15216 - sampled from the toy Poddle dog - (MIC> 32 µg/ml).
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due to mutations in the gene encoding the enzyme sterol-14α-de-
methylase. These mutations were found in the resistant strain isolated
in Japan [6]. This theory could benefit from the availability of the re-
sistant strains we have deposited in a culture collection, which can be
used for further experiments.
In conclusion, this case shows that the development of azole re-
sistance of clinical relevance is possible for strains of M. pachydermatis
harbored by dogs. However, it is important to emphasize that the un-
ique conditions that lead to resistance (an unusually long azole treat-
ment necessary to treat an “idiopathic” and chronic overgrowth of
Malassezia) are uncommon in clinical practice.
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